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Evaluation of MR imaging ﬁndings
differentiating cavernous haemangiomas
from schwannomas in the orbit
Abstract
Objective It is important to distinguish
between orbital cavernous haeman-
gioma and schwannoma because the
treatments of choice for the two
tumours are different. The aim was to
evaluate MR imaging ﬁndings distin-
guishing the two tumours. Methods
Magnetic resonance imaging includ-
ing T1- and T2-weighted imaging and
contrast-enhanced MR imaging was
performed in 43 patients with caver-
nous haemangiomas and 16 patients
with schwannomas conﬁrmed by
pathology. Location, conﬁguration,
margins, signal intensity, homogene-
ity and enhancement pattern of the
tumour were retrospectively eval-
uated. Results There was a signiﬁcant
difference between cavernous
haemangiomas and schwannomas
regarding the location, conﬁguration
and margins of the mass, signal
intensity and homogeneity on T1- and
T2-weighted imaging, the spread pat-
tern of contrast enhancement, the
enhancement pattern and the type of
time–intensity curve (P<0.05).
Markedly homogeneous hyperinten-
sity signal on T2-weighted imaging





schwannomas have different MR
imaging features that could be helpful
in the differentiation between the
tumours. The spread pattern of the
contrast enhancement on dynamic
contrast-enhanced MR imaging is the
most reliable ﬁnding distinguishing
cavernous haemangiomas from
schwannomas.
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Introduction
Cavernous haemangioma is the most common primary
orbital tumour in adults, accounting for 6% of all orbital
lesions [1–3]. Orbital schwannomas are benign peripheral
nerve sheath tumours and constitute 1% of all orbital
tumours [1, 3]. Orbital cavernous haemangiomas and
schwannomas present as slow progressive enlargement
and the most common presenting sign and symptom is
painless proptosis [4–8]. Although both orbital cavernous
haemangiomas and schwannomas share many similar
clinical and radiological characteristics [5–8], it is impor-
tant to distinguish between the tumours because they
demonstrate important different features and the treat-
ments of choice for the two are different [3, 7–9].
Magnetic resonance imaging, especially dynamic MR
imaging, plays a crucial role in the differentiation of
orbital cavernous haemangiomas and schwannomas [7, 8,
10–14]. The spread pattern of the contrast enhancement on
dynamic contrast-enhanced MR imaging is considered the
most important ﬁnding distinguishing the two tumours
[10–14]. However, the literature on MR imaging ﬁndings
in the differentiation of these two tumours is based on
small patient populations [12]. Consequently, this study
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aims to assess MR imaging ﬁndings distinguishing orbital
cavernous haemangiomas from schwannomas and to
elaborate on speciﬁc differences between the two tumours.
Materials and methods
Patient population
Between June 2004 and February 2009, 43 patients with
cavernous haemangiomas and 16 patients with schwanno-
mas conﬁrmed by pathological results were enrolled in the
protocol. MR imaging including T1- and T2-weighted
imaging and contrast-enhanced MR imaging was per-
formed in all 59 patients. Most patients presented with
painless insidious proptosis. Some patients demonstrated a
limitation of extraocular motion, diplopia and strabismus.
Informed consent was obtained from all patients for
anonymous performance of radiological studies and
analysis of clinical data. Our institutional review board
approved the study protocol.
MR imaging
Magnetic resonance imaging was performed on a General
Electric (GE) Signa 1.5-T MR imaging system (GE
Healthcare, Milwaukee, WI, USA) with an eight-channel
head coil.
MR imaging was performed with T1-weighted (repeti-
tion time/echo time, 400/15 ms) and T2-weighted (3,000/
120) fast spin-echo images. A 16-cm ﬁeld of view, a 3-
mm-thick section at 0 interval, and a 288×256 matrix with
two signals acquired were used. Dynamic contrast-
enhanced (DCE) MR imaging was performed by using a
fast spoiled gradient recalled (FSPGR) sequence with 8.4/
4 ms, a ﬂip angle of 15°, one excitation, a matrix of 256×
160, a ﬁeld of view of 220×220 mm, and a section
thickness of 3.2 mm at 0 interval. A power injector
(Medrad, Indianola, PA, USA) with an injection ﬂow rate
of 2 mL/s was used. The acquisition of the dynamic
images began concurrently with the initiation of the
injection of 0.1 mmol of gadopentetate dimeglumine
(Magnevist, Schering, Berlin, Germany) per kilogram.
The contrast material injection was followed by a 20-mL
saline ﬂush. Each MR sequence yielded 12 anatomical
slices in 13 s; this was repeated 12 times with an interval
between each sequence of 12 s. Total imaging time was
288 s (4 min 48 s).
DCE MR imaging was evaluated by using a GE AW
4.2 workstation (GE Healthcare). A region of interest
(ROI) was drawn manually on the dynamic images for
assessment of the enhancement kinetics. We chose the
area that demonstrated the greatest degree of early
enhancement so that the time–intensity curve (TIC) could
be generated. The area of the ROI typically was 8 mm2.
The contrast index (CI) was calculated from: CI=[(signal
intensity post-contrast)−(signal intensity pre-contrast)]/
(signal intensity pre-contrast). Tpeak was the time to peak
enhancement. The TICs were analysed qualitatively as
wash-out, persistent or plateau-shaped curves.
Image interpretation
Magnetic resonance imaging features including DCE MR
imaging were retrospectively evaluated by an experienced
head and neck radiologist (15 years’ experience). Loca-
tion, conﬁguration, margins, signal intensity, homogeneity
and enhancement pattern of the tumour were assessed.
The location was deﬁned as anterior orbit (anterior orbit is
deﬁned as the orbit anterior to the posterior ethmoidal
artery), posterior orbit (posterior orbit is deﬁned as the
orbit posterior to the posterior ethmoidal artery), or both
anterior and posterior orbit; extraconal or intraconal space;
superior or inferior orbit; and nasal or temporal orbit. The
conﬁguration was deﬁned as round, ovoid or irregular.
The margin was deﬁned as smooth or lobulated. On
contrast-enhanced MR imaging including DCE MR
imaging, the spread pattern of the contrast enhancement,
enhancement pattern, CI and type of TIC were evaluated.
The spread pattern of the contrast enhancement was
divided into two groups: one starting from a small point
or portion and the other starting from a wide area.
“Progressive” enhancement means that on early imaging
after the injection, one small point or portion of enhance-
ment was initially noted, then contrast media progres-
sively ﬁlled up the tumour and eventually the mass
showed total and homogeneous enhancement (Fig. 1)
[13]. Other patterns of enhancement included gradually
heterogeneous enhancement and gradually homogeneous
enhancement.
Statistical analysis
Frequency distribution of individual MR imaging features
in cavernous haemangiomas was compared with that in
schwannomas with Chi-squared tests. Fisher’s exact test
was performed when the sample size in the subgroups was
deemed too small. A P value of less than 0.05 was
considered to represent a signiﬁcant difference.
Results
Tables 1 and 2 describe the frequency distribution of non-
enhanced MR imaging features (Table 1) and contrast-
enhanced MR imaging features (Table 2). There was a
signiﬁcant difference between cavernous haemangiomas
and schwannomas regarding the location (including
anterior orbit, posterior orbit, or both anterior and
posterior orbit; extraconal or intraconal space), conﬁg-
uration and margins of the mass, signal intensity and
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homogeneity on T1- and T2-weighted imaging, the spread
pattern of the contrast enhancement, enhancement pattern
and type of time–intensity curve (TIC) (P<0.05) (Figs. 1,
2, 3).
Orbital cavernous haemangiomas were always a well-
deﬁned, ovoid, intraconal mass with markedly homoge-
neous hyperintensity signal on T2-weighted imaging.
Schwannomas often demonstrated a heterogeneously
isointense or mildly hyperintense mass in the intraconal
or extraconal space.
After gadolinium administration, all 43 cavernous
haemangiomas showed enhancement starting from a small
point or portion and contrast media ﬁlling up the tumour
later, i.e. “progressive” enhancement (Fig. 1). Compared
with the cavernous haemangiomas, all 16 schwannomas
showed enhancement starting from a wide area and
heterogeneous or homogeneous enhancement later (Fig. 2).
Discussion
Orbital cavernous haemangiomas, the most common
primary orbital tumour in adults, demonstrate a predilec-
tion to affect middle-aged women (60–70%), with a mean
age of 43 to 48 years and range of 18 to 72 years based on
several large series [4, 7, 9]. The most common presenting
sign and symptom of the orbital cavernous haemangioma
Fig. 1 A 54-year-old woman with a cavernous haemangioma. a
Axial T1-weighted imaging demonstrated an oval intraconal
isointense tumour relative to muscle. b The tumour appeared
hyperintense (arrowhead) relative to muscle on axial T2-weighted
imaging. c–e Dynamic MR images obtained at 25, 75 and 225 s,
respectively, after administration of gadopentetate dimeglumine,
showed enhancement starting from one point of peripheral portion
of the tumour (arrowhead). f Post-contrast T1-weighted imaging
with fat saturation showed further enlargement of enhancement
regions (arrowhead)
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is painless proptosis. In the past, orbital cavernous
haemangiomas were invariably resected because they
could not be conclusively discerned from other tumours
clinically or radiologically [4]. However, orbital cavernous
haemangiomas have recently been classiﬁed as type 3
low-ﬂow arteriovenous malformations with a direct
arterial in-ﬂow and venous out-ﬂow mechanism (arterial
low-ﬂow type) rather than as true neoplasms or proliferat-
ing hamartomas [15], and, to our knowledge, there is no
evidence of malignant transformation in the literature.
Moreover, CT and MR imaging, especially MR imaging,
have evolved to deliver high sensitivity and speciﬁcity in
diagnosing orbital cavernous haemangiomas and distin-
guishing cavernous haemangiomas from other tumours,
which have played a vital role in accurate diagnosis and
correct treatment planning [5, 7, 12, 14, 16]. Therefore,
Table 1 Frequency distribution of non-enhanced MR imaging features
MR imaging feature Type of tumour P value
Overall Haemangioma Schwannoma
N % N % N %
No. of patients 59 43 16
Anterior or posterior orbit 0.004
Anterior 47 79.6 39 90.8 8 50
Posterior 6 10.2 2 4.6 4 25
Both 6 10.2 2 4.6 4 25
Extraconal or intraconal space 0.049
Intraconal 44 74.6 35 81.4 9 56.2
Extraconal 15 25.4 8 18.6 7 43.8
Nasal or temporal orbit 0.250
Nasal 26 44.1 17 39.5 9 56.2
Temporal 33 55.9 26 60.5 7 43.8
Superior or inferior orbit 0.937
Superior 29 49.2 21 48.8 8 50
Inferior 30 50.8 22 51.2 8 50
Conﬁguration 0.015
Round 6 10.2 4 9.3 2 12.6
Ovoid 50 84.7 39 90.7 11 68.7
Irregular 3 5.1 0 0 3 18.7
Margin 0.531
Smooth 44 74.6 33 76.7 11 68.7
Lobulated 15 25.4 10 23.3 5 31.3
T1 signal intensitya <0.001
Hypointense 7 11.9 0 0 7 43.7
Isointense 52 88.1 43 100 9 56.3
T1 homogeneity <0.001
Homogeneous 50 84.7 43 100 7 43.7
Heterogeneous 9 15.3 0 0 9 56.3
T2 signal intensitya 0.001
Isointense 5 8.5 0 0 5 31.3
Hyperintense 54 91.5 43 100 11 68.7
T2 homogeneity <0.001
Homogeneous 46 78 43 100 3 18.7
Heterogeneous 13 22 0 0 13 81.3
a Signal intensity was compared with that of extraocular muscle
Table 2 Frequency distribution of contrast-enhanced MR imaging features
MR imaging feature Type of tumour P value
Overall Haemangioma Schwannoma
N % N % N %
No. of patients 59 43 16
Spread pattern of contrast enhancement <0.001
Starting from a small point or portion 43 72.9 43 100 0 0
Starting from a wide area 16 27.1 0 0 16 100
Enhancement pattern <0.001
Homogeneous or heterogeneous 16 27.1 0 0 16 100
Progressive 43 72.9 43 100 0 0
CI 1.8±0.6 1.4±0.3 0.003
TIC type <0.001
Persistent 12 20.3 3 7 9 56.2
Plateau-shaped 24 40.7 19 44.2 5 31.3
Wash-out 23 39 21 48.8 2 12.50
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recent literature supports observation as an alternative to
surgical excision for asymptomatic orbital cavernous
haemangiomas and surgery can be withheld until vision
is threatened or cosmetic appearance resulting from
proptosis is unacceptable [3, 9].
Orbital schwannomas, constituting 1% of all orbital
tumours, are benign peripheral nerve sheath tumours
originating purely from Schwann cells and usually seen
in young to middle-aged adults and rarely in children [3].
Clinical ﬁndings of orbital schwannomas are generally
similar to those of cavernous haemangiomas, but they are
somewhat more likely to exhibit progressive growth and
symptoms. Thus, surgical excision is the treatment of
choice for orbital schwannomas, different from orbital
cavernous haemangiomas [3, 7–9].
Our results demonstrate that, in presence of a well-
deﬁned, ovoid, intraconal mass with markedly homoge-
neous hyperintensity signal on T2-weighted imaging,
one small point or portion of enhancement initially
noted after administration of contrast medium and
“progressive” enhancement on later enhancement
images, favours the diagnosis of cavernous haeman-
gioma instead of schwannoma.
Most orbital cavernous haemangiomas are identiﬁed in
the intraconal space, predominantly in the lateral aspect of
the intraconal space [7, 9]. In our series, only 8 of the 43
orbital cavernous haemangiomas were in the extraconal
space. However, orbital schwannomasmore commonly arise
from sensory nerves in the orbit, speciﬁcally the supra-
orbital, supratrochlear and lacrimal nerves, and thus are
Fig. 2 A 42-year-old man with a schwannoma. a Axial T1-weighted
imaging showed an oval extraconal isointense tumour relative to
muscle. b Axial T2-weighted imaging revealed that the tumour was
isointense relative to muscle (arrowhead). c–e Dynamic MR images
obtained at 25, 75 and 225 s, respectively, after administration of
gadopentetate dimeglumine showed enhancement starting from wide
areas of tumour (arrowhead). f Axial post-contrast T1-weighted
imaging with fat saturation showed homogeneous enhancement of
the tumour (arrowhead)
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usually outside the orbital muscle cone [16]. The nasociliary
nerve is the only division of the ophthalmic nerve within the
annular tendon [8]. Therefore, orbital schwannomas can be
seen as an intraconal or extraconal mass. In our series, the
frequency of the schwannoma being located in the extraco-
nal or intraconal space is almost the same.
Orbital cavernous haemangiomas appear isointense to
muscle on T1-weighted imaging and hyperintense to
muscle on T2-weighted imaging [5, 7]. Although non-
contrast MR imaging ﬁndings are non-speciﬁc, they may
offer some advantage in the differentiation of orbital
cavernous haemangiomas by demonstrating marked
hyperintensity signal to muscle with internal septations
on T2-weighted imaging, a hypointense circumferential
rim corresponding to the ﬁbrous pseudocapsule, and
chemical shift artefact in the frequency-encoded direction
secondary to high water content within the lesion
surrounded by orbital fat [5, 7, 17]. Orbital schwannoma
is isointense with respect to the extraocular muscle on T1-
weighted images and mildly hyperintense on T2-weighted
images [6, 18]. Orbital schwannomas may undergo
cavitary change, which appears as a cystic mass with
straw-coloured ﬂuid on gross pathological examination
and looks homogeneously hypointense to muscle on T1-
weighted images and hyperintense on T2-weighted images
[8, 19]. Consequently, markedly homogeneous hyper-
intensity signal on T2-weighted imaging is one of the
reliable ﬁndings distinguishing the two tumours.
Variable degrees of contrast enhancement observed in
orbital cavernous haemangiomas were reported, probably
related to variable imaging times after contrast medium
infusion. However, multiphase dynamic contrast CT and
MRI demonstrated virtually pathognomonic imaging
features of orbital cavernous haemangiomas [5, 7, 17].
On early imaging after the injection, one small point or
portion of enhancement is initially noted because of its
low-ﬂow arterial supply, and the slow progressive accu-
mulation of contrast medium continues within the dilated
vascular spaces ﬁlling in centrally during the late venous
phase. Subsequently, homogeneous contrast enhancement
occurs and persists in the delayed equilibrium phases [7,
12–16]. This enhancement pattern is referred to as a
“progressive” enhancement pattern in the literature [10,
11, 13]. Similar enhancement pattern is shared by
cavernous haemangioma in the cavernous sinus and liver
[20]. Several multiphase dynamic contrast MR imaging
protocols have been reported for studying orbital cav-
ernous haemangiomas [7, 11, 12, 14].
Compared with orbital cavernous haemangiomas, no
“progressive” enhancement pattern was found in orbital
schwannomas [12, 18]. Therefore, our results and the
literature showed that the “progressive” enhancement
pattern will be the most reliable ﬁnding in distinguishing
orbital cavernous haemangiomas from schwannomas.
Some reports in the literature indicated that orbital
cavernous haemangiomas showed an initial central point or
Fig. 3 A 47-year-old woman with schwannoma. aObliquely sagittal
T1-weighted imaging identiﬁed an irregular extraconal tumour with
isointensity of the anterior portion of the tumour (arrow) and slight
hypointensity of the posterior portion (arrowhead) relative to muscle.
b Axial T2-weighted imaging showed isointensity of the anterior
portion of the tumour (arrow) and hyperintensity of the posterior
portion (arrowhead) relative to muscle. c Obliquely sagittal post-
contrast T1-weighted imaging demonstrated enhancement of the
anterior portion of the tumour (arrow) and no enhancement of the
posterior portion (arrowhead)
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portion enhancement after administration of gadopentetate
dimeglumine [7, 12–14]. However, our results show that
enhancement starts from one peripheral point or portion of
the tumour in most orbital cavernous haemangiomas. The
initial enhancement point represents the connecting point of
feeding vessels to the lesion, which is useful for estimating
the connecting point of the feeding vessels [14].
An unexpected result is that nearly half of orbital
cavernous haemangiomas demonstrate a wash-out TIC type
frequently seen in the malignant tumour rather than a
plateau-shaped or persistent TIC type. This may be because
contrast medium ﬁlls one portion of the tumour during an
early phase after administration of contrast medium and
contrast medium diffuses into adjacent spaces through the
foramen of the ﬁbrous interstitium between spaces at a later
phase [12–14]. Thus it results in a decrease in concentration
of contrast media in the portion of the tumour ﬁlled by
contrast media during the early phase.
There is a signiﬁcant difference in TIC type between
orbital cavernous haemangiomas and schwannomas in
contrast to a previous report that there is no signiﬁcant
difference in TIC type between the two tumours [12]. This is
probably because we chose an ROI covering the greatest
degree of early enhancement rather than the whole tumour.
Recent literature on dynamic MR imaging in the breast, soft
tissue and orbital masses indicates that an ROI covering the
greatest degree of early enhancement of the mass reﬂects
haemodynamic alterations of the tumour better than an ROI
covering the whole tumour [10, 21, 22].
The multiphase dynamic contrast MR imaging ﬁndings
of orbital cavernous haemangiomas have been described
in the literature [10–14]. However, our results provided
additional information on dynamic contrast-enhanced MR
imaging ﬁndings of orbital cavernous haemangiomas.
First, short imaging time and interval of every phase on
dynamic contrast MR imaging may accurately show one
point or small portion of enhancement of the mass on
early phase images after the injection of contrast medium
and allow characterization of speciﬁc spread pattern of the
contrast enhancement in small orbital cavernous haeman-
giomas, which can differentiate small orbital cavernous
haemangiomas from small schwannomas and other
tumours. Second, TIC type of orbital cavernous haeman-
gioma is signiﬁcantly different from that of schwannoma.
Previous literature showed small haemangiomas could
not be differentiated from haemangiopericytomas as their
enhancement appears early and strongly and calciﬁcation
could be noticed in cavernous haemangiomas, contribu-
ting to the differential diagnosis [5, 7]. However,
calciﬁcation is occasionally seen in cavernous haemangio-
mas and plays a limited role in the differential diagnosis.
Our results revealed that strong enhancement starting from
a wide area and rapid wash-out on DCE MR imaging were
seen in haemangiopericytomas that might be helpful in the
differential diagnosis.
Capillary haemangiomas are a different sort of haeman-
giomatous tumour that are more common in children, often
regress and have a different imaging appearance [5, 7].
Conclusion
Cavernous haemangiomas and schwannomas have differ-
ent MR imaging features including the location, conﬁg-
uration and margins of the mass, signal intensity and
homogeneity on T1- and T2-weighted imaging, the spread
pattern of contrast enhancement, the enhancement pattern
and TIC type, which could be helpful in the differentiation
of the two tumours. The spread pattern of the contrast
enhancement on dynamic contrast-enhanced MR imaging
is the most reliable ﬁnding distinguishing cavernous
haemangiomas and schwannomas. Markedly homogene-
ous hyperintensity signal on T2-weighted imaging is
another reliable ﬁnding distinguishing the two tumours.
MR imaging, especially dynamic contrast-enhanced MR
imaging, plays a vital role in the differential diagnosis of
cavernous haemangiomas and schwannomas.
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